title: Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer.
abstract: Although some patients are initially sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), resistance invariably develops. Therefore, it's very important to study the molecular mechanism of this resistance. In our previous study we found that integrin beta1 can induce EGFR TKIs resistance in non-small cell lung cancer (NSCLC) cells. Here we analyzed the association of integrin beta1 and c-MET that is a recognized mechanism of EGFR TKIs resistance in NSCLC to demonstrate the mechanism of integrin beta1 related EGFR TKIs resistance. We found that the ligands of integrin beta1 and c-MET could synergistically promote cell proliferation and their inhibitors could synergistically improve the sensitivity to gfitinib, increase apoptosis, and inhibit the downstream signal transduction: focal adhesion kinase (FAK) and AKT. On the other hand, ligand-dependent activation of integrin beta1 could induce EGFR TKIs resistance through activating c-MET and its downstream signals. Thus, it can be concluded that there is crosstalk between integrin beta1 and c-MET and integrin beta1 mediates EGFR TKI resistance associating with c-MET signaling pathway in non-small cell lung cancer.
authors: Cancer Institute, Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Medical School, 507 Zhengmin Road, Shanghai, 200433, China. caicunzhou@yahoo.com.cn.
authors: Lixia
authors: L
authors: Ju
authors: Caicun
authors: C
authors: Zhou
references: Oncol Rep. 1998 Sep-Oct;5(5):1013-24
references: 9683803
references: Oncogene. 1992 Jun;7(6):1149-57
references: 1317541
references: J Carcinog. 2008;7:9
references: 19240370
references: J Clin Invest. 2012 Apr;122(4):1529-40
references: 22378044
references: Int J Radiat Biol. 2009 Nov;85(11):923-8
references: 19895268
references: Breast Cancer Res. 2011 Aug 31;13(4):R84
references: 21884573
references: Mol Cancer Ther. 2011 Dec;10(12):2257-66
references: 21980133
references: Leuk Lymphoma. 2010 Jun;51(6):1090-7
references: 20470221
references: J Cell Sci. 2004 May 1;117(Pt 11):2227-37
references: 15126624
references: PLoS Med. 2005 Mar;2(3):e73
references: 15737014
references: J Cell Biochem. 2010 Dec 15;111(6):1565-74
references: 21053345
references: Dev Cell. 2007 Oct;13(4):496-510
references: 17925226
references: Cancer Res. 2003 Sep 1;63(17):5462-9
references: 14500382
references: Br J Cancer. 2006 Dec 4;95(11):1483-9
references: 17106442
references: Cancer Res. 2003 Nov 1;63(21):7345-55
references: 14612533
references: PLoS One. 2007 Mar 07;2(3):e269
references: 17342203
references: Int J Cancer. 2005 Aug 10;116(1):36-44
references: 15761868
references: Exp Cell Res. 2008 Jan 15;314(2):309-16
references: 17910952
references: Mol Biol Cell. 2000 Jul;11(7):2485-96
references: 10888683
references: N Engl J Med. 2005 Feb 24;352(8):786-92
references: 15728811
references: Blood. 2008 Apr 1;111(7):3562-70
references: 18198349
references: BMC Cell Biol. 2005 Feb 17;6(1):8
references: 15717924
references: J Biol Chem. 2012 May 18;287(21):17065-17076
references: 22457358
references: J Clin Oncol. 2006 Jul 20;24(21):3340-6
references: 16785471
references: Cancer Res. 2009 Nov 15;69(22):8620-8
references: 19887601
references: Oncogene. 2011 Mar 31;30(13):1566-76
references: 21119598
references: Int J Biochem Cell Biol. 1999 Dec;31(12):1357-62
references: 10641789
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: J Cell Physiol. 2009 Feb;218(2):294-303
references: 18844239
references: Int J Cancer. 1999 Nov 26;83(5):640-9
references: 10521801
references: Oncogene. 2011 Sep 29;30(39):4087-96
references: 21478906
references: Curr Opin Cell Biol. 2006 Oct;18(5):516-23
references: 16919435
references: Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70
references: 15897464